盐酸帕罗西汀单用与合用小剂量舒必利治疗伴有躯体症状抑郁症患者60例疗效观察

目的探讨盐酸帕罗西汀联合小剂量舒必利治疗伴躯体症状抑郁症的疗效与安全性。方法 60例符合CCMD-3抑郁症诊断标准并伴有明显躯体症状的患者,入组后随机分为两组,分别采用单用帕罗西汀和帕罗西汀联用小剂量舒必利分别治疗6周。采用汉密尔顿抑郁量表（HAMD）于治疗前及治疗后2、4、6周进行疗效评定,采用副反应量表（TESS）评定药物不良反应。结果两组治疗前后HAMD分值比较差异有统计学意义,同时两组间疗效比较也有统计学意义。不良反应评分差异无统计学意义。结论帕罗西汀联合小剂量舒必利治疗伴有躯体症状抑郁症患者与单用帕罗西汀比较具有疗效好、安全性、依从性较高的优点,适合临床应用。

A clinical efficacy observation of paroxetine combined with sulpirid in the treatment of depression with somatic symptoms

Objective To explore the effect and safety of paroxetine combined with sulpiride in the treatment of depression with somatic symptoms.Methods A total of 60 depression patients with somatic symptoms by CCMD-3 were randomly divided into paroxetine combined with sulpiride group and paroxetine group to treat for 6 weeks.Hamilton Depression Rating Scale（HAMD）and Treatment Emergent Symptom Scale（TESS） were used to assess the efficacy and side effects before and after treatment.Results The scores of HAMD had significant differences between before and after treatment in two groups,and the significant differences were found between two groups.Side effects had no significant differences in two groups.Conclusion Paroxetine combined with small dose of sulpiride in the treatment of depression with somatic symptoms have better efficacy,few side effects and higher compliance than paroxetine.